Opendata, web and dolomites

MBLIs SIGNED

New Approaches to Metallo-β-Lactamase Inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MBLIs project word cloud

Explore the words cloud of the MBLIs project. It provides you a very rough idea of what is the project "MBLIs" about.

public    unlike    lactamases    esi    spends    biology    modified    spectrum    acids    31p    caused    global    human    organic    denaturing    relevance    pioneer    infections    rendering    dcc    protein    enzymes    structurally    binding    pbps    clinical    critical    broad    inspire    structural    mbl    penicillin    lactam    breadth    variations    clinically    panel    screening    metallo    gt    resistance    die    contain    inactive    therapies    almost    combination    hydrolysis    beta    bacterial    society    selectivity    ms    60    inhibition    mbli    mbls    small    biological    catalyse    inhibitors    serine    occurrence    ring    mechanistically    antibiotics    synthesis    25    serious    alarming    representing    molecules    active    healthcare    nmr    unrelated    inhibited    clear    phosphonates    situation    sbl    pathogens    mechanisms    efficacy    health    patients    compounds    antibiotic    phosphinic    desired    resistant    representative    bla    equilibrated    sites    generation    obtain    threat    structures    mblis    interdisciplinary    least    directed    mechanism    blas    little    coupled    billion    reporter    chemistry    medicinal    dcls    declining    utility   

Project "MBLIs" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://schofield.chem.ox.ac.uk/mariosmarkoulides.aspx
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 183˙454.00

Map

 Project objective

The increasing problem of antibiotic resistance is a major global public health concern. In the EU 25,000 patients die each year due to infections caused by multi-resistant bacterial pathogens, and the EU spends at least 1.5 billion euro per year on healthcare costs. The β-lactam antibiotics are the most important antibiotics representing >60% of small molecules in clinical use. BLAs contain a β-lactam ring which is critical for penicillin-binding protein inhibition. However, BLA efficacy is declining due to resistance mechanisms including the widespread occurrence of β-lactamases, which catalyse β-lactam hydrolysis. Metallo-β-lactamases, long-considered as of little clinical relevance, now present a serious global threat to almost all BLAs, rendering the development of approaches to MBL inhibitors important. Unlike the serine β-lactamases, the MBLs are structurally and mechanistically unrelated to PBPs, and are not inhibited by current mechanism-based SBL inhibitors. Due to variations in MBL structures, a major challenge in MBL inhibition is the development of compounds with the breadth of selectivity necessary for clinical utility. Society is now in an alarming situation and there is a clear need for the development of an MBLI:β-lactam-based combination therapies. The aim of my proposed work is to pioneer, enable and inspire the generation of broad-spectrum MBLIs active against a panel of clinically representative MBLs, but inactive against human enzymes with related active sites. To obtain the desired objective, novel approaches are proposed and include the use of phosphonates and phosphinic acids for: (a) MBL-directed DCC coupled to analysis by non-denaturing ESI-MS and 31P-NMR, (b) 31P-NMR reporter screening method, (c) pre-equilibrated DCLs for MBL-directed DCC, and (d) the synthesis of modified inhibitors. The study will be interdisciplinary and encompass organic synthesis, biological MS/NMR, structural biology, and medicinal chemistry.

 Publications

year authors and title journal last update
List of publications.
2016 David Yuxin Wang, Martine I Abboud, Marios S Markoulides, Jürgen Brem, Christopher J Schofield
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
published pages: 1063-1084, ISSN: 1756-8919, DOI: 10.4155/fmc-2016-0078
Future Medicinal Chemistry 8/10 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MBLIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MBLIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

SAInTHz (2020)

Structuration of aqueous interfaces by Terahertz pulses: A study by Second Harmonic and Sum Frequency Generation

Read More